What Has Changed? A Comprehensive Review of U.S. Drug Policy Over the Last Decade

Recent Trends

Over the past several years, U.S. drug policy has shifted notably from punitive enforcement toward a mix of harm reduction, decriminalization, and regulated legalization at the state level. Key developments include:

• More than half of states have legalized cannabis for medical use, and a growing number have approved adult recreational use, creating a patchwork of state laws that conflict with federal prohibition.
• The federal government has moved to reschedule cannabis from a Schedule I to a Schedule III controlled substance under the Controlled Substances Act, a step that could reshape research and commercial regulations.
• Opioid settlement funds—distributed through multistate agreements—have been directed toward treatment, prevention, and recovery services in many communities.
• Several jurisdictions have experimented with decriminalizing possession of small amounts of certain drugs, focusing instead on treatment referrals and social services.

Background

For decades, U.S. drug policy was driven by the “War on Drugs,” emphasizing strict law enforcement, mandatory minimum sentences, and federal scheduling that placed most controlled substances into the most restrictive categories. Over the last ten years, a bipartisan consensus has emerged that this approach led to mass incarceration without proportional reductions in drug misuse. Policymakers have increasingly cited public health principles, recognizing addiction as a chronic condition rather than solely a criminal justice issue. This shift has been accompanied by a surge in overdose deaths, particularly from synthetic opioids, which accelerated calls for a more pragmatic response. Federal agencies have expanded access to medication-assisted treatment and naloxone distribution, while state legislatures have passed bills to limit criminal penalties for low-level offenses.

User Concerns

Individuals directly affected by drug policy changes face several practical uncertainties:

• Criminal records: Many people still carry convictions for acts that have since been decriminalized or legalized elsewhere, leading to questions about expungement processes and eligibility under changing state laws.
• Access to treatment: While funding for addiction services has increased, waiting lists for residential beds and medication-assisted treatment remain long in many regions, particularly rural areas.
• Legal gray areas: Cannabis users in states where it is legal face conflicts with federal law, especially regarding employment drug testing, housing eligibility, and firearms ownership.
• Product safety: In unregulated or newly regulated markets, users have no guarantee of product purity, potency, or the absence of adulterants—a concern that has grown with the spread of synthetic drugs.

Likely Impact

If the trajectory of the last decade continues, the following outcomes are anticipated by policy analysts:

• A continued decline in arrests for simple drug possession, reducing the prison population and mitigating racial disparities observed in enforcement patterns.
• Expanded medical research into cannabis and psychedelics, as federal rescheduling lowers regulatory barriers for clinical trials and pharmaceutical development.
• Increased state-level experimentation with safe consumption sites and pilot programs for limited decriminalization, though federal prosecution risks may constrain implementation.
• Greater emphasis on data-driven allocation of opioid settlement funds, with local governments prioritizing overdose prevention and harm reduction services over enforcement-only strategies.
• Potential for new regulatory frameworks—similar to alcohol and tobacco—for cannabis, though interstate commerce and banking remain unresolved issues without congressional action.

What to Watch Next

Several developments warrant close attention over the coming months and years:

• The final rule on federal cannabis rescheduling and whether it is challenged in court, which would affect the timeline for broader changes.
• Legislation advancing in Congress to provide legal protections for state-legal cannabis operations, such as the SAFE Banking Act, and to ease research restrictions.
• The impact of state-level psychedelic legalization efforts—particularly for psilocybin therapy—on federal scheduling and potential rescheduling initiatives.
• How the next administration approaches the interplay between drug policy and border security, as synthetic drugs continue to enter the country through multiple channels.
• Ongoing litigation over the authority of the Drug Enforcement Administration to penalize physicians who prescribe controlled substances for addiction treatment, which could affect access to buprenorphine and methadone.